journal
MENU ▼
Read by QxMD icon Read
search

Inflammatory Bowel Diseases

journal
https://www.readbyqxmd.com/read/28520589/distance-to-specialist-care-and-disease-outcomes-in-inflammatory-bowel-disease
#1
Nienke Z Borren, Grace Conway, William Tan, Elizabeth Andrews, John J Garber, Vijay Yajnik, Ashwin N Ananthakrishnan
BACKGROUND: Optimal treatment of inflammatory bowel disease (IBD) requires specialized health care. Patients frequently travel long distances to obtain care for IBD, which may hinder regular care and affect outcomes adversely. METHODS: This study included patients with established Crohn's disease or ulcerative colitis receiving care at a single referral center between January 2005 and August 2016. Distance to our health care center from the zip code of residence was determined for each patient and classified into quartiles...
May 16, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28520588/evaluation-of-the-quality-of-semen-and-sexual-function-in-men-with-inflammatory-bowel-disease
#2
Paz Valer, Alicia Algaba, Daniel Santos, Manuel E Fuentes, Elva Nieto, Javier P Gisbert, Pilar López, Elvira Quintanilla, Francisco J García-Alonso, Iván Guerra, Álvaro Páez, Fernando Bermejo
BACKGROUND: Data on fertility rates and medication safety in men with inflammatory bowel disease (IBD) are limited. The aim of this study was to evaluate whether there is a seminal alteration in patients with IBD and, if so, to evaluate the mechanisms that may play a role according to what has been described in the literature. Its secondary aim was to evaluate the impact on male sexual function of IBD. METHODS: Multicenter, cross-sectional, case series study comparing men with IBD and control subjects...
May 16, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28520587/complementary-roles-of-nod2-in-hematopoietic-and-nonhematopoietic-cells-in-preventing-gut-barrier-dysfunction-dependent-on-mlck-activity
#3
Ziad Al Nabhani, Nicolas Montcuquet, Maryline Roy, Monique Dussaillant, Jean-Pierre Hugot, Frédérick Barreau
BACKGROUND: Crohn's disease (CD) pathogenesis is multifactorial involving genetic and environmental factors. Loss of function mutations in the nucleotide oligomerization domain 2 (NOD2) gene are the main genetic risk factor for CD. Like patients with CD, Nod2 mice are characterized by an enhanced Th1 immune response and a defective mucosal barrier function evidenced by increased intestinal permeability. We previously showed that the latter is related to hematopoietic Nod2 deficiency. Our aim was to explore the mechanisms by which Nod2 expressed in the hematopoietic and in the nonhematopoietic compartments interplay to control epithelial paracellular permeability...
May 16, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28520586/clinical-course-of-ulcerative-colitis-after-liver-transplantation-in-patients-with-concomitant-primary-sclerosing-cholangitis-and-ulcerative-colitis
#4
Mohammad Reza Fattahi, Seyyed Ali Malek-Hosseini, Gholam Reza Sivandzadeh, Ali Reza Safarpour, Kamran Bagheri Lankarani, Ali Reza Taghavi, Fardad Ejtehadi
BACKGROUND: The natural history of ulcerative colitis (UC) after liver transplantation (LT) for primary sclerosing cholangitis (PSC) remains ill defined. This study aimed to evaluate the course of UC after LT for PSC. METHODS: The course of UC, including the clinical colitis severity index, was evaluated in patients with concomitant PSC and UC who received LT for PSC-induced end-stage liver disease. A total of 167 (55.4%) patients with PSC had concurrent inflammatory bowel disease (IBD)...
May 16, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28509769/commentary-on-variations-in-health-insurance-policies-regarding-biological-therapy-use-in-ibd-and-a-modified-delphi-process-for-the-development-of-choosing-wisely-for-ibd
#5
https://www.readbyqxmd.com/read/28509768/modified-delphi-process-for-the-development-of-choosing-wisely-for-inflammatory-bowel-disease
#6
Geoffrey C Nguyen, Karen Boland, Waqqas Afif, Brian Bressler, Jennifer L Jones, Adam V Weizman, Sharyle Fowler, Smita Halder, Vivian W Huang, Gilaad G Kaplan, Reena Khanna, Sanjay K Murthy, Joannie Ruel, Cynthia H Seow, Laura E Targownik, Tanya Chawla, Luis Guimaraes, Aida Fernandes, Sherif Saleh, Gil Y Melmed
BACKGROUND AND AIMS: The prevalence and incidence of inflammatory bowel disease (IBD) in North America is among the highest in the world and imparts substantial direct and indirect medical costs. The Choosing Wisely Campaign was launched in wide variety of medical specialties and disciplines to reduce unnecessary or harmful tests or treatment interventions. METHODS: The Choosing Wisely list for IBD was developed by the Canadian IBD Network for Research and Growth in Quality Improvement (CINERGI) in collaboration with Crohn's and Colitis Canada (CCC) and the Canadian Association of Gastroenterology (CAG)...
May 15, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28509767/variations-in-health-insurance-policies-regarding-biologic-therapy-use-in-inflammatory-bowel-disease
#7
Abhijeet Yadav, Joshua Foromera, Ilana Feuerstein, Kenneth R Falchuk, Joseph D Feuerstein
BACKGROUND: The American Gastroenterological Association (AGA) has developed guidelines for the management of ulcerative colitis and Crohn's disease (CD) recommending anti-TNF therapy in moderate-severe disease. However, which drug is used is often dictated by insurance company policies. We sought to determine the insurance policy requirements prior to approval of biologic therapies. METHODS: Using the National Association of Insurance Commissioners report of the top 125 insurance companies by market share in 2014, we reviewed the first 50 that had online policies regarding anti-TNF and vedolizumab available...
May 15, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28498159/fecal-calprotectin-is-not-affected-by-pregnancy-clinical-implications-for-the-management-of-pregnant-patients-with-inflammatory-bowel-disease
#8
Mette Julsgaard, Christian L Hvas, Richard B Gearry, Thea Vestergaard, Jan Fallingborg, Lise Svenningsen, Jens Kjeldsen, Miles P Sparrow, Signe Wildt, Jens Kelsen, Sally J Bell
BACKGROUND: Noninvasive biomarkers of inflammation for monitoring inflammatory bowel disease (IBD) are important in pregnancy. Clinical and laboratory markers are often affected by the physiological adaption that occurs during pregnancy, although, few, if any, data exist on fecal calprotectin (FC). We investigated FC concentrations in pregnant controls and IBD women, and whether FC correlated with physician global assessment (PGA), C-reactive protein (CRP), and Harvey-Bradshaw Index (HBI)/Simple Clinical Colitis Activity Index (SCCAI) before and after pregnancy, as well as during each trimester...
May 11, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28498158/transmural-healing-is-associated-with-improved-long-term-outcomes-of-patients-with-crohn-s-disease
#9
Samuel R Fernandes, Rita V Rodrigues, Sónia Bernardo, João Cortez-Pinto, Isadora Rosa, João P da Silva, Ana R Gonçalves, Ana Valente, Cilénia Baldaia, Paula M Santos, Luís Correia, José Venâncio, Paula Campos, António D Pereira, José Velosa
BACKGROUND: Mucosal healing (MH) is currently accepted as one of the best treatment targets in Crohn's disease. However, even in patients with sustained MH, residual bowel wall inflammation can still be detected by cross-sectional imaging. The long-term benefits of obtaining transmural healing (TH) have not been previously assessed. METHODS: We performed an observational study including 214 patients with Crohn's disease with a magnetic resonance enterography (MRE) and colonoscopy performed within a 6-month interval...
May 11, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28498157/compositional-changes-in-the-gut-mucus-microbiota-precede-the-onset-of-colitis-induced-inflammation
#10
Maria Glymenaki, Gurdeep Singh, Andrew Brass, Geoffrey Warhurst, Andrew J McBain, Kathryn J Else, Sheena M Cruickshank
BACKGROUND: Inflammatory bowel disease (IBD) is associated with an inappropriate immune response to the gut microbiota. Notably, patients with IBD reportedly have alterations in fecal microbiota. However, the colonic microbiota occupies both the gut lumen and the mucus covering the epithelium. Thus, information about mucus-resident microbiota fails to be conveyed in the routine microbiota analyses of stool samples. Further, studies analyzing microbiota in IBD have mainly focused on stool samples taken after onset of inflammation...
May 11, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28498156/coping-with-inflammatory-bowel-disease-engaging-with-information-to-inform-health-related-decision-making-in-daily-life
#11
Gayle J Restall, Alexandria M Simms, John R Walker, Clove Haviva, Lesley A Graff, Kathryn A Sexton, Norine Miller, Laura E Targownik, Charles N Bernstein
BACKGROUND: People with inflammatory bowel disease (IBD) require disease and lifestyle information to make health-related decisions in their daily lives. Derived from a larger qualitative study of the lived experiences of people with IBD, we report on findings that explored how people with IBD engage with health-related information in their daily lives. METHODS: Participants were recruited primarily from the Manitoba IBD Cohort Study. We used purposive sampling to select people with a breadth of characteristics and experiences...
May 11, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28498155/therapeutic-drug-monitoring-to-guide-infliximab-dose-adjustment-is-associated-with-better-endoscopic-outcomes-than-clinical-decision-making-alone-in-active-inflammatory-bowel-disease
#12
Orlaith B Kelly, Sarah Oʼ Donnell, Joanne M Stempak, A Hillary Steinhart, Mark S Silverberg
BACKGROUND: Adequate infliximab (IFX) levels are associated with favorable outcomes in inflammatory bowel disease. Using therapeutic drug monitoring (TDM) to guide dosing is cost effective and associated with clinical improvement, but effect on endoscopic outcomes remains unclear. METHODS: Primary responders to IFX who underwent dose escalation (2008-2014) were reviewed. Patients with active endoscopic disease were included. Two cohorts were examined: TDM-based decision to escalate (TDM) and clinical decision (non-TDM)...
May 11, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28498154/pediatric-to-adult-transition-and-medication-adherence-in-patients-with-inflammatory-bowel-disease
#13
Jayson Jeganathan, Cheng Hiang Lee, Antony Rahme, Darren K Tiao, Celine Weston, Shoma Dutt, Annabel Magoffin, Vu Kwan, Aladdin Alswaifi, Peter H Katelaris, Kevin J Gaskin, Edward V OʼLoughlin, Rupert W Leong
BACKGROUND: Medication nonadherence is common in inflammatory bowel disease and is associated with poor outcomes. There has been no study on pediatric-to-adult transition as a risk factor for nonadherence in inflammatory bowel disease, which has been demonstrated in other diseases. We aimed to assess whether transitioned (TR) patients have higher nonadherence rates than young adults (YAs) diagnosed in adulthood. METHODS: Consecutive ambulatory subjects were prospectively recruited and completed the validated Medication Adherence Reporting Scale (MARS), with the primary outcome being adherence differences between group age-matched TR and YA groups...
May 11, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28498153/infliximab-trough-levels-at-induction-to-predict-treatment-failure-during-maintenance
#14
Claire Liefferinckx, Charlotte Minsart, Jean-François Toubeau, Anneline Cremer, Leila Amininejad, Eric Quertinmont, Jacques Devière, Ann Gils, André van Gossum, Denis Franchimont
BACKGROUND: Infliximab (IFX) is indicated for the treatment of inflammatory bowel diseases (IBD). Nevertheless, loss of response (LOR) to IFX is reported in up to 10% to 30% of patients within the first year of treatment. Our objective was to evaluate the impact of the pharmacokinetics of IFX at induction on treatment failure. METHODS: This is a longitudinal cohort study on 269 patients with IBD treated with IFX in a single center. A total of 2331 blood samples were prospectively collected from 2007 until March 2015 with a retrospective analysis of clinical data...
May 11, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28505052/beyond-efficacy-the-acceptability-of-antidepressant-treatment-to-patients-with-inflammatory-bowel-disease
#15
Christopher W P Hopkins, Harun S Butt, Calum D Moulton
No abstract text is available yet for this article.
May 10, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28498152/oligoclonal-t-cell-receptor-repertoire-in-colonic-biopsies-of-patients-with-microscopic-colitis-and-ulcerative-colitis
#16
Sezin Günaltay, Dirk Repsilber, Gisela Helenius, Nils Nyhlin, Johan Bohr, Olof Hultgren, Elisabeth Hultgren Hörnquist
BACKGROUND: Microscopic colitis (MC), comprising collagenous colitis (CC) and lymphocytic colitis (LC), is a type of variation of inflammatory bowel diseases. Local T-cell infiltration in the mucosa plays a major role in MC immunopathology. METHODS: To understand diversity and clonality of infiltrating T cells, we analyzed the T-cell receptor beta (TCRβ) chains in colonic biopsies of MC, ulcerative colitis (UC), and their remission counterparts (CC/LC-HR [histological remission] or UC-R [remission]) compared with patients with noninflamed colons using next-generation sequencing...
May 10, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28486256/one-year-clinical-outcomes-in-an-ibd-cohort-who-have-previously-had-anti-tnfa-trough-and-antibody-levels-assessed
#17
Donal Tighe, Barry Hall, Shivashini Kirthi Jeyarajah, Sinead Smith, Niall Breslin, Barbara Ryan, Deirdre McNamara
BACKGROUND: Loss of response (LOR) is a big concern for anti-TNFa therapies in inflammatory bowel disease. Immunomonitoring may be useful to optimize response rates and overcome secondary LOR. METHODS: This was an observational retrospective cohort study of a group of patients with inflammatory bowel disease on infliximab (IFX) and adalimumab (ADA) who had anti-TNFa trough and antibody levels measured, during maintenance phase of treatment. Anti-TNFa trough and antibody levels were measured using standard enzyme-linked immunosorbent assay techniques...
May 5, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28486255/intestinal-barrier-disruption-in-ileal-pouchitis-after-ileal-pouch-anal-anastomosis-in-a-rat-model
#18
Kai-Yu Li, Jian-Lin Wang, Yan-Yan Xu, Sen-Yang Gao, Ying-Ying Zhang, An-Qi He, Gang Liu
BACKGROUND: Pouchitis occurs in approximately 50% of patients with ulcerative colitis after ileal pouch-anal anastomosis (IPAA) but the pathogenesis remains unclear. We used a rat model of dextran sulfate sodium (DSS)-induced ileal pouchitis to examine whether intestinal barrier disruption plays a role in the development and progression of the disease. METHODS: Rats were randomly divided into DSS (underwent IPAA and administered 5% DSS orally), IPAA (underwent IPAA), and Sham groups (underwent switch abdominal surgery)...
May 5, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28471836/interleukin-17a-inhibitor-induced-crohn-s-disease-beh%C3%A3-et-s-disease-like-lesions
#19
Hisashi Shiga, Sho Fukuda, Katsunori Iijima
No abstract text is available yet for this article.
May 2, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28471835/early-life-exposure-lifestyle-and-comorbidity-as-risk-factors-for-microscopic-colitis-a-case-control-study
#20
Bas P M Verhaegh, Marieke J Pierik, Danny Goudkade, Yvette S M T Cuijpers, Ad A M Masclee, Daisy M A E Jonkers
BACKGROUND: The pathophysiology of microscopic colitis (MC) is not fully understood. A dysregulation of the adaptive immune response has been hypothesized, of which the maturation and function is imprinted in early life. Various other factors (e.g., hormonal factors) have also been found to be associated, sometimes, with minimal or conflicting evidence. The aims of this study were to evaluate whether an exposure to (microbial) agents in early life might be protective for MC development and to assess the role of several less well-established risk factors in one study...
May 2, 2017: Inflammatory Bowel Diseases
journal
journal
32277
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"